Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Vascular Magnetics (Philadelphia, PA) a development-stage medical device focused on magnetically targeted drug delivery for the treatment of peripheral artery disease, closed a $7M Series A financing. Participants include Devon Park Bioventures. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Pulse Therapeutics (St. Louis, MO) a development-stage medical device company focused on vascular drug delivery device for blood clots in stroke patients , closed a $3.1M Series B financing. Participants include BioGenerator.

Pulse Therapeutics (St. Louis, MO) a development-stage medical device company focused on vascular drug delivery device for blood clots in stroke patients, closed a $3.1M Series B financing. Participants include BioGenerator.

Arsenal Medical (Watertown, MA) a development-stage biotech company focused on nanofiber drug delivery and therapeutic foams to accommodate complex anatomies,closed $3M Series A financing. Participants include Polaris Venture Partners, North Bridge Venture Partners and Intersouth Partners.

480 Biomedical (Waltham, MA) a development-stage biopharmaceutical company focused on bioresorbable scaffold for treating occlusive disease in the femoral artery, closed $15M Series A financing. Participants include Polaris Venture Partners, North Bridge Venture Partners and Intersouth Partners.

Tangent Medical Technologies (Ann Arbor, MI) a development-stage medical device company focused on peripheral intravenous delivery systems, closed a $4.5M Series A financing. Participants include Arboretum Ventures, Flagship Ventures and Osage Ventures.

Innopharma (Piscataway, NJ) a development-stage specialty pharmaceutical company focused on generics and drug delivery technology platforms for existing drugs, closed a $15M Series A financing. Participants include Thomas, McNerney & Partners.

Valeritas (Bridgewater, NJ) a commercial-stage developer of a disposable insulin delivery device, closed a $150M Series C financing. Participants include Welsh, Carson, Anderson & Stowe, MPM Capital, Pitango Venture Capital, Abingworth Management, Advanced Technology Ventures, Onset Ventures, HLM Venture Partners, Agate Medical Investments, CHL Medical Partners and Kaiser Permanente Ventures.

Activaero (Germany) a clinical-stage medical device company focused on inhaled pulmonary drug delivery, a $6.8M Series B financing. Participants include Life Sciences Partners, BioMedPartners, VI Partners, Abalis Finance, Vesalius Biocapital and MedVenture Partners.

DBV Technologies (France) a clinical-stage drug:device biopharma company focused on non invasive immunotherapy delivery for food allergies, closed a $25.5M Series C financing. Participants include InnoBio Fund, Lundbeckfond Ventures, ALTO Invest, Sofinnova Partners, ALK Abello and Apax Partners.

Civitas Therapeutics (Chelsea, MA) a preclinical-stage dry powder pulmonary delivery platform and device combination company focused on for Parkinson’s disease, closed a $20M Series A financing. Participants include Longitude Capital and Canaan Partners.

Pantech Biosolutions (Liechtenstein) a clinical-stage device company focused on a laser-based transdermal delivery system for large-molecular weight drugs, closed a $19M Series B financing. Participants include StemCell Holding and Gamma Capital Partners.

Ensysce Biosciences (Houston, TX) a development-stage biopharma company focused on carbon nanotube complexes for chemotherapeutic transport, closed a $1.5M Series A financing. Participants include Texas Emerging Technology Fund.

« Previous Entries  Next Page »

to top of page...